The Medicines Co. is in late-stage studies of a drug, inclisiran, meant to lower cholesterol. Novartis has a pattern of acquiring other companies in recent years to expand its portfolio of drugs. “We’re hoping to reimagine treatment of the leading global cause of death. This could be a strong step forward in Novartis’ transformation into a focused medicines company,” Novartis CEO Vas Narasimhan tweeted Sunday.
The Medicines Co. focuses on researching treatments for cardiovascular disease, specifically looking at ways to lower so-called bad cholesterol. The deal is expected to close early next year.